These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 19699696

  • 21. Commentary: Sorafenib use in patients with advanced hepatocellular carcinoma and underlying Child-Pugh B cirrhosis: evidence and controversy.
    Zhu AX, Clark JW.
    Oncologist; 2009 Jan; 14(1):67-9. PubMed ID: 19147690
    [No Abstract] [Full Text] [Related]

  • 22. Sorafenib-induced destructive thyroiditis.
    Iavarone M, Perrino M, Viganò M, Beck-Peccoz P, Fugazzola L.
    Thyroid; 2010 Sep; 20(9):1043-4. PubMed ID: 20825302
    [No Abstract] [Full Text] [Related]

  • 23. Doxorubicin plus sorafenib in treatment of advanced hepatocellular carcinoma.
    Pazo Cid RA, Lao J, Lanzuela M.
    JAMA; 2011 Feb 23; 305(8):781; author reply 781. PubMed ID: 21343576
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Major achievements in hepatocellular carcinoma.
    Bruix J, Llovet JM.
    Lancet; 2009 Feb 21; 373(9664):614-6. PubMed ID: 19231618
    [No Abstract] [Full Text] [Related]

  • 27. Baying for a flexible drug price.
    Lancet; 2009 Nov 28; 374(9704):1794. PubMed ID: 19944844
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Sorafenib use in hepatocellular carcinoma in Japan: early experience and impact on clinical practice.
    Zhu AX.
    Clin Drug Investig; 2012 Aug 08; 32 Suppl 2():1-2. PubMed ID: 22873622
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. What is the indication for sorafenib in hepatocellular carcinoma? A clinical challenge.
    Kim R, Byrne MT, Tan A, Aucejo F.
    Oncology (Williston Park); 2011 Mar 08; 25(3):283-91, 295. PubMed ID: 21548473
    [Abstract] [Full Text] [Related]

  • 32. The role of sorafenib in hepatocellular carcinoma.
    Gholam P.
    Clin Adv Hematol Oncol; 2015 Apr 08; 13(4):232-4. PubMed ID: 26352581
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. PDGFRalpha: a new therapeutic target in the treatment of hepatocellular carcinoma?
    Oseini AM, Roberts LR.
    Expert Opin Ther Targets; 2009 Apr 08; 13(4):443-54. PubMed ID: 19335066
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.